Commentary RE: Androgen Deprivation with Radiation Therapy Compared with Radiation Therapy Alone for Locally Advanced Prostatic Carcinoma: A Randomized Comparative Trial of the Radiation Therapy Oncology Group⁎⁎

  • Rahul D. Tendulkar
    Address correspondence to: Rahul D. Tendulkar, M.D., Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue Desk CA-5, Cleveland, OH 44195.
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
    Search for articles by this author
      The significance of the RTOG 8610 randomized trial continues to endure well over 2 decades after its initial publication. While it had been previously known that prostate cancers are driven by testosterone, this was among the first randomized trials to prospectively test whether the addition of combined androgen blockade could improve outcomes over radiation therapy alone. At the time of trial inception in 1986, the PSA blood test was still gaining acceptance but had not yet been universally adopted as a screening tool for the detection of prostate cancer. Thus the majority of patients at the time were diagnosed on the basis of an abnormal digital rectal exam, and patients with locally advanced disease formed the subjects of this study.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect